Pranax

Pranax is a biotechnology company that develops and commercializes regenerative medicine solutions centered on exosome technology licensed from leading research institutions to support tissue repair, immune modulation, and healthspan goals. Its work focuses on harnessing stem cell-derived exosomes as foundational biological agents that can be formulated into physician-directed supplements, therapeutic products, and personalized biological services designed to address inflammation, aging-associated decline, and tissue damage through evidence-based science. The company combines proprietary manufacturing methods with clinical and research insights to produce exosome-based offerings and to explore applications across wellness, longevity, and regenerative care. Pranax also provides exosome banking services that enable personalized collection and preservation of extracellular vesicles for potential future use in health programs. Its platform integrates advanced biological engineering with analytical frameworks to support translational research and product development in regenerative biology. The company engages scientific collaborators and technical teams to expand its portfolio of exosome-derived products and to investigate therapeutic pathways that leverage cellular communication mechanisms for improved biological function.

Domain

pranax.com

Country

United States

Industry

Biopharma

Employees

11-50

Last Funding

$17.0M

Founded

2022